Compass Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Compass Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($66.49M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($49.38M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($42.49M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($39.23M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($82.18M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($29.50M) | Mar 18, 2022 |
| FY2020 | Mar 31, 2020 | ($37.5K) | Jun 8, 2020 |
| FY2020 | Dec 31, 2019 | ($34.74M) | Mar 5, 2021 |
| FY2020 | Mar 31, 2019 | ($36.0K) | Jun 8, 2020 |
| FY2019 | Mar 31, 2018 | ($35.1K) | Jul 1, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($72.84M) | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | ($56.63M) | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | ($50.36M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($41.66M) | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | ($81.88M) | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | ($27.81M) | Mar 18, 2022 |
| FY2020 | Mar 31, 2020 | ($32.1K) | Jun 8, 2020 |
| FY2020 | Dec 31, 2019 | ($34.05M) | Mar 5, 2021 |
| FY2020 | Mar 31, 2019 | ($32.8K) | Jun 8, 2020 |
| FY2019 | Mar 31, 2018 | ($35.0K) | Jul 1, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $219.59M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $140.40M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $156.88M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $199.65M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $153.76M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $51.91M | Mar 18, 2022 |
| FY2020 | Mar 31, 2020 | $3.7K | Jun 8, 2020 |
| FY2020 | Dec 31, 2019 | $30.38M | Mar 5, 2021 |
| FY2020 | Mar 31, 2019 | $4.9K | Jun 8, 2020 |
| FY2019 | Mar 31, 2018 | $25 | Jul 1, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.80M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $15.17M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $8.34M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $18.01M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $13.68M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $11.97M | Mar 18, 2022 |
| FY2020 | Mar 31, 2020 | $111.8K | Jun 8, 2020 |
| FY2020 | Dec 31, 2019 | $19.11M | Mar 5, 2021 |
| FY2020 | Mar 31, 2019 | $75.5K | Jun 8, 2020 |
| FY2019 | Mar 31, 2018 | $34.6K | Jul 1, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $196.79M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $125.23M | Mar 5, 2026 |
| FY2025 | Dec 31, 2023 | $148.54M | Mar 5, 2026 |
| FY2024 | Dec 31, 2022 | $181.64M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $140.08M | Mar 21, 2024 |
| FY2022 | Dec 31, 2020 | $39.95M | Mar 15, 2023 |
| FY2020 | Mar 31, 2020 | ($108.1K) | Jun 8, 2020 |
| FY2021 | Dec 31, 2019 | $11.27M | Mar 18, 2022 |
| FY2020 | Mar 31, 2019 | ($70.6K) | Jun 8, 2020 |
| FY2020 | Dec 31, 2018 | ($84.77M) | Mar 5, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | (1) | Mar 15, 2023 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.64M | Mar 5, 2026 |
| FY2025 | Dec 31, 2024 | $43.48M | Mar 5, 2026 |
| FY2024 | Dec 31, 2023 | $24.23M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $34.95M | Mar 21, 2024 |
| FY2022 | Dec 31, 2021 | $144.51M | Mar 15, 2023 |
| FY2021 | Dec 31, 2020 | $47.08M | Mar 18, 2022 |
| FY2020 | Mar 31, 2020 | $3.7K | Jun 8, 2020 |
| FY2020 | Dec 31, 2019 | $25.30M | Mar 5, 2021 |
| FY2020 | Mar 31, 2019 | $4.9K | Jun 8, 2020 |